• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by IN8bio Inc.

    8/11/23 4:18:55 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INAB alert in real time by email
    SC 13G 1 d514664dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    IN8bio, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 Par Value Per Share

    (Title of Class of Securities)

    45674E 109

    (CUSIP Number)

    August 3, 2021

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 45674E 109       Page 2 of 8 Pages

     

      1.    

      Name of Reporting Persons

     

      Transcend Partners Opportunity Fund I LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      4,111,958(1) (3)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      4,111,958(1) (3)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,111,958(1) (3)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      13.0%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Consists of shares of Common Stock held by Transcend Partners Opportunity Fund I LLC (“Transcend”). Any action with respect to the shares of Common Stock held by Transcend, including voting and dispositive decisions, requires at least a majority vote of its managing members, Grant Fairbairn, Nina Fairbairn, and Scott Kintz, each of whom disclaim beneficial ownership of such shares.

    (2) 

    The calculation is based on 31,601,145 shares of Common Stock of the Issuer outstanding as of August 7, 2023 as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2023.

    (3) 

    Reports holdings as of August 10, 2023.


    CUSIP No. 45674E 109       Page 3 of 8 Pages

     

      1.    

      Name of Reporting Persons

     

      Emily Fairbairn

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      196,081(1) (4)

       6.   

      Shared Voting Power

     

      91,336(2) (4)

       7.   

      Sole Dispositive Power

     

      196,081(1) (4)

       8.   

      Shared Dispositive Power

     

      91,336(2) (4)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      287,417(1) (2) (4)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.9% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Consists of (i) 27,706 shares of Common Stock held by Emily T. Fairbairn Roth IRA, (ii) 119,042 shares of Common Stock held directly by Ms. Fairbairn and (iii) 49,333 shares of Common Stock underlying outstanding options held by Ms. Fairbairn that are immediately exercisable or will be immediately exercisable within 60 days of August 10, 2023.

    (2) 

    Consists of 91,336 shares of Common Stock held by Valley High Limited Partnership (“Valley High”). Ms. Fairbairn’s spouse is the sole managing partner of Valley High. Accordingly, Ms. Fairbairn disclaims beneficial ownership of the shares held by Valley High except to the extent of her pecuniary interest therein.

    (3) 

    The calculation is based on dividing (a) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 31,601,145 shares of Common Stock of the Issuer outstanding as of August 7, 2023 as reported by the Issuer on its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2023, and (ii) 49,333 shares of Common Stock underlying outstanding options held by Ms. Fairbairn that are immediately exercisable or will be immediately exercisable within 60 days of August 10, 2023.

    (4) 

    Reports holdings as of August 10, 2023.


    CUSIP No. 45674E 109       Page 4 of 8 Pages

     

    Explanatory Note

    This Schedule 13G (this “Statement”) reports the shares of common stock, par value $0.0001 per share (the “Common Stock”), of IN8bio, Inc., a Delaware corporation (the “Issuer”), beneficially owned by Transcend Partners Opportunity Fund I LLC (“Transcend”) and Emily Fairbairn (“Ms. Fairbairn”) (collectively, the “Reporting Persons”) as of August 10, 2023. This Statement also includes certain disclosures for which a Schedule 13D and Amendment No. 1 thereto were previously inadvertently not filed by the Reporting Persons as of August 3, 2021 and August 16, 2022, respectively. In addition, this Statement constitutes an “exit” filing by Ms. Fairbairn.

     

    Item 1(a).

    Name of Issuer

    IN8bio, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices

    350 5th Avenue, Suite 5330

    New York, NY 10118

     

    Item 2(a).

    Name of Person Filing

    This Schedule 13G (this “Statement”) is filed by Transcend Partners Opportunity Fund I LLC (“Transcend”) and Emily Fairbairn (Ms. Fairbairn) (collectively, the “Reporting Persons”).

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence

    The principal business address of each of the Reporting Persons is as follows:

    10 Orinda View Road

    Orinda, CA 94563

     

    Item 2(c).

    Citizenship

    The citizenship of each of the Reporting Persons is the United States of America.

     

    Item 2(d).

    Title of Class of Securities

    Common Stock, $0.0001 par value per share

     

    Item 2(e).

    CUSIP Number

    45674E 109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership

    (a) Amount beneficially owned: See responses to Item 9 on each cover page.

    (b) Percent of class: See responses to Item 11 on each cover page.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: See responses to Item 5 on each cover page.


    CUSIP No. 45674E 109       Page 5 of 8 Pages

     

    (ii) Shared power to vote or to direct the vote: See responses to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on each cover page.

    On August 3, 2021, the closing date of the Issuer’s initial public offering of shares of Common Stock (the “Offering”), the sole manager of Transcend was Ms. Fairbairn, who has served as a director of the Issuer since the Offering. Accordingly, at such time, Ms. Fairbairn was deemed to beneficially own the shares of Common Stock held by Transcend.

    In connection with the Offering, Transcend purchased 100,000 shares of Common Stock for an aggregate purchase price of $1.0 million. Following the Offering, Transcend beneficially owned 3,322,485 shares of Common Stock, representing 17.7% of the then-outstanding shares of Common Stock, and Ms. Fairbairn beneficially owned 3,441,527 shares of Common Stock, representing 18.4% of the then-outstanding shares of Common Stock. Except for the 91,336 shares of Common Stock held by Valley High Limited Partnership (“Valley High”), of which Ms. Fairbairn’s spouse is the sole managing partner, Ms. Fairbairn had sole voting and sole dispositive power over the shares of Common Stock beneficially owned by her.

    In connection with the Issuer’s follow-on offering on August 16, 2022 (the “Follow-On Offering”), Transcend purchased 789,473 shares of Common Stock for an aggregate purchase price of $1.5 million. Following the Follow-On Offering, Transcend beneficially owned 4,111,958 shares of Common Stock, representing 16.8% of the then-outstanding shares of Common Stock, and Ms. Fairbairn beneficially owned 4,264,158 shares of Common Stock, representing 17.4% of the then-outstanding shares of Common Stock. Except for the 91,336 shares of Common Stock held by Valley High, of which Ms. Fairbairn’s spouse is the sole managing partner, Ms. Fairbairn had sole voting and sole dispositive power over the shares of Common Stock beneficially owned by her.

    Effective July 28, 2023, any action with respect to the shares of Common Stock held by Transcend, including voting and dispositive decisions, requires at least a majority vote of its managing members, Grant Fairbairn, Nina Fairbairn, and Scott Kintz, each of whom disclaim beneficial ownership of such shares of Common Stock. Accordingly, as of July 28, 2023, Ms. Fairbairn no longer has voting or dispositive control over the shares of Common Stock held by Transcend.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.  ☒

    Effective July 28, 2023, Ms. Fairbairn ceased to be the beneficial owner of more than five percent of the Common Stock. As of August 10, 2023, Transcend remains a beneficial owner of more than five percent of the Common Stock as disclosed on the cover page for Transcend.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.


    CUSIP No. 45674E 109       Page 6 of 8 Pages

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Exhibit List

    Exhibit 1: Joint Filing Agreement


    CUSIP No. 45674E 109       Page 7 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 11, 2023

     

    TRANSCEND PARTNERS OPPORTUNITY FUND I LLC
    By:   /s/ Nina Fairbairn

    Name: Nina Fairbairn

    Title: Managing Member

    EMILY FAIRBAIRN
    By:   /s/ Emily Fairbairn

    Name: Emily Fairbairn

     

    Get the next $INAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INAB

    DatePrice TargetRatingAnalyst
    3/18/2024$7.50Buy
    Laidlaw
    8/30/2022$14.00Buy
    H.C. Wainwright
    1/24/2022$19.00 → $9.00Buy
    B. Riley Securities
    8/24/2021$12.00Buy
    Mizuho
    8/23/2021$19.00Buy
    B. Riley Securities
    More analyst ratings

    $INAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

      NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recently reached a significant clinical milestone. The patient, with a grade 4, IDH-mutant glioma, has been in remission and surviving for 4 years having been treated with INB-200. The patient is doing well, has returned to work and has a good quality of life post-treatment with INB-200. Patient 009's clinical progress and 4-year remission far surpasses progression-free outcomes observed in other clinical

      6/9/25 7:00:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

      Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos

      6/2/25 7:30:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

      Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in patients with chronic disease and dysfunctional immune systems, low γδ T cell levels Broad Therapeutic Potential and Potential for Safer Treatments: The data suggest INB-619 can uniquely deliver deep immune clearance without trig

      5/14/25 8:00:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Graff Jeremy R.

      4 - IN8BIO, INC. (0001740279) (Issuer)

      5/12/25 4:15:22 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fairbairn Emily

      4 - IN8BIO, INC. (0001740279) (Issuer)

      5/12/25 4:15:20 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Greenwood Luba

      4 - IN8BIO, INC. (0001740279) (Issuer)

      5/12/25 4:15:24 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on IN8bio with a new price target

      Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50

      3/18/24 8:14:30 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on IN8bio with a new price target

      H.C. Wainwright initiated coverage of IN8bio with a rating of Buy and set a new price target of $14.00

      8/30/22 7:19:37 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities reiterated coverage on IN8bio with a new price target

      B. Riley Securities reiterated coverage of IN8bio with a rating of Buy and set a new price target of $9.00 from $19.00 previously

      1/24/22 9:01:28 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INAB
    SEC Filings

    See more
    • SEC Form 8-K filed by IN8bio Inc.

      8-K - IN8BIO, INC. (0001740279) (Filer)

      6/30/25 8:30:27 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by IN8bio Inc.

      8-K - IN8BIO, INC. (0001740279) (Filer)

      6/4/25 8:00:19 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by IN8bio Inc.

      8-K - IN8BIO, INC. (0001740279) (Filer)

      6/2/25 7:36:42 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INAB
    Financials

    Live finance-specific insights

    See more
    • IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

      Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos

      6/2/25 7:30:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

      100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this link to participate or access the listen-only version of the webcast here NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company devel

      2/11/25 8:00:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

      100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clini

      6/13/24 4:01:00 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INAB
    Leadership Updates

    Live Leadership Updates

    See more
    • IN8bio Appoints Dr. Corinne Epperly to Board of Directors

      Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. "Dr. Epperly brings an incredible range of ex

      12/7/23 8:00:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

      Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly's oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors

      5/1/23 8:00:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board

      NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. He joins the other world-renowned experts in oncology, cellular immunotherapy and immunology on IN8bio's SAB who provide expertise, contribute insights and advise the Comp

      9/8/22 7:30:00 AM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by IN8bio Inc.

      SC 13D/A - IN8BIO, INC. (0001740279) (Subject)

      10/11/24 6:01:16 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by IN8bio Inc.

      SC 13G - IN8BIO, INC. (0001740279) (Subject)

      10/9/24 5:19:20 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IN8bio Inc.

      SC 13G/A - IN8BIO, INC. (0001740279) (Subject)

      9/17/24 7:30:50 PM ET
      $INAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care